GlobeNewswire

Clean Motion presents Re:volt - an electric delivery van that charges itself with the help of the sun.

Share

The Swedish electric vehicle company Clean Motion presents Re:volt - their next generation electric vehicle. A compact, strong, and modular delivery van, developed to meet the huge demand for sustainable last-mile transports in cities. The new solar panel roof makes it energy-efficient enough to eliminate the need for charging when the sun is up. The start of production is planned for the fall of 2022 and right now they are looking for partners to optimize the customer offer.

Re:volt is small on the outside and big on the inside. The design is clean, functional and the modular construction means that the vehicle can be easily configured according to the customer's wishes. The range will be up to 400 km - with 100 km per day just from the sun, thanks to the innovative solar panel roof.

“We are not alone in integrating solar panels into vehicles. What is unique is the energy efficiency of our vehicles, which means that the solar-roof can make them self-sufficient in energy. It also means that with only 40 kg of batteries we can offer a range of 280 km, which will suit northern latitudes where the sun is not a reliable energy source, ”says Göran Folkesson, CEO of Clean Motion.

The combination of rapidly increasing home deliveries and ambitious climate goals creates very interesting opportunities for electric vehicles with high energy efficiency. When the vehicle fleet is going from a few single percent electric, to almost 100 percent, comes the real challenge for society and the automotive industry. Here, Re:volt has a great advantage, as it solves many transport missions with a minimal need for charging.

“The market for environmentally friendly last mile deliveries is huge and rapidly growing, but the range of vehicles that can really replace the old fossil fueled vans is not that exciting. With Re:volt, we want to change the image of what a small electric vehicle can do - and start a green revolution in city deliveries, ”says Göran Folkesson.

Re:volt will start rolling out at the end of 2022. Right now they are looking for companies with diversified transport needs, who want to be involved and to adapt the last details of the platform. The goal is to create a comprehensive customer offering for the European transport market. As with Zbee, the plan is to offer Re:volt for local licensed manufacturing in emerging markets globally.

This is Re:volt:
Efficient and innovative solar panel roof that adds up to 100 kilometers extra range per day.
– Small on the outside but big on the inside. All dimensions are standardized and tailored to fit goods All dimensions are adapted for standardized goods handling.
– High load-carrying capacity in relation to the low vehicle weight. Re:volt uses the energy to transport the goods, rather than the vehicle itself.
– Flexible platform that is adaptable to the area of use. For example, the battery range can be set from 70 to 280 kilometers.

Re:volt – key figures, basic version:
Dimensions: 3000 x 1400 x 1700 mm (LxWxH)
Weight without load: 250 kg
Maximum weight: 700 kg
Cargo space: 2500 liter
Maximum range from batteries: 70–280 km
Maximum range from solar energy: 130 km/day, depending on geography

For further information, please contact:
Göran Folkesson
CEO, Clean Motion AB
Phone: +46 70 611 26 98
Email: goran@cleanmotion.se

Christoffer Sveder
Director Commercial Operations, Clean Motion AB
Phone: +46 70 611 26 98
Email: christoffer@cleanmotion.se

About Clean Motion AB
Clean Motion AB is a Swedish company that manufactures and sells electric vehicles. The company's vision is to develop truly sustainable products that the vast mass of the world's population can afford to use. The company's electric vehicle, the Zbee, is light, has a high efficiency and thus a very good operating economy. Clean Motion provides the market with safe and energy-efficient vehicles for a sustainable urban traffic environment.

Clean Motion AB is listed on First North at Nasdaq Stockholm. Certified Adviser is G&W Fondkommission, e-mail:
ca@gwkapital.se, Telephone: 08- 503 000 50. For further information, please visit: www.cleanmotion.se

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

After safety review The Connection study is now again open to recruit the smallest infants.22.9.2021 22:30:00 CEST | Press release

After safety review The Connection study is now again open to recruit the smallest infants. Following the completion of the DMC (Data Monitoring Committee) safety review, IBT is pleased to announce the continuation of the recruitment of patients between 500 - 1000g (Strata A and B) in the Connection study. “Given the vulnerability of the Stratum A population, infants with a birth weight less than 750 gram, we have agreed with the FDA to carefully monitor the safety of these infants. Therefore, the independent DMC has completed an additional safety review, and there are no objections to continue the study. We expect recruitment to increase as we now again recruit in two strata. ” Says Staffan Strömberg, Chief Executive Officer of IBT. About Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The company’s Class B shares are listed on Nasdaq Stockholm, Mid-cap (IBT B). Infant Bacterial Therapeutics AB (publ) (“IBT”) is a p

Efter säkerhetsgranskning har rekryteringen av de minsta barnen i the Connection study återupptagits.22.9.2021 22:30:00 CEST | Pressemelding

Efter säkerhetsgranskning har rekryteringen av de minsta barnen i the Connection study återupptagits. Efter att säkerhetsgranskningen som utförts av Data Monitoring Committee (DMC) har slutförts kan IBT nu lämna det glädjande beskedet att rekryteringen av spädbarn i båda viktgrupperna, 500–1000 gram (Strata A och B), kan fortsätta. ”Med anledning av att spädbarnen i stratum A, som har en födelsevikt på mindre än 750 gram, är mycket känsliga har vi enats med FDA om att övervaka säkerheten för dessa spädbarn mycket noggrant. Den oberoende DMC har med anledning av detta slutfört en extra säkerhetsgranskning där det inte föreligger några invändningar mot att fortsätta studien. Vi förväntar oss att rekryteringstakten kommer att öka när vi återigen kan rekrytera i två strata. ” säger Staffan Strömberg, VD för IBT. Om Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (”IBT”) är ett publikt bolag med säte i Stockholm. Bolagets aktier av serie B handlas på Nasdaq Stockholm, Mid

Weekly share repurchase program transaction details22.9.2021 19:34:35 CEST | Press release

September 22, 2021 SBM Offshore reports the transaction details related to its EUR150 million (c. US$180 million) share repurchase program for the period September 16, 2021 through September 22, 2021. The repurchases were made under the EUR150 million share repurchase program announced on and effective from August 5, 2021. The objective of the program is to reduce share capital and, in addition, to provide shares for regular management and employee share programs. Information regarding the progress of the share repurchase program and the aggregate of the transactions (calculated on a daily basis) for the period August 5, 2021 through September 22, 2021 can be found in the top half of the table below. Further detailed information regarding both the progress of the share repurchase program and all individual transactions can be accessed via the Investors section of the Company’s website. Share Repurchase Program Overall progress Share Repurchase Program: Total Repurchase Amount EUR 150,0

21Shares Announces Listing of Six Additional Crypto ETPs on Deutsche Boerse XETRA22.9.2021 19:11:35 CEST | Press release

Firm is first and only to give investors access to 10 crypto listings in Germany September 22, 2021 – 21Shares AG (“21Shares”), the world’s largest issuer of cryptocurrency ETPs, today announced the listing of six additional cryptocurrency ETPs for a total of 10 on Deutsche Boerse XETRA, Germany’s top trading venue for exchange traded funds. The new crypto ETPs include Solana ETP (Ticker: 21XL GY), Polkadot ETP (Ticker: PDOT GY), Cardano ETP (Ticker: DADA GY), Stellar Lumens ETP (Ticker: XLME GY), Tezos (Ticker: 21XZ GY), and the Crypto Basket Index ETP (Ticker:21XH GY). Hany Rashwan, Co-Founder and CEO of 21Shares said, “We are pleased to expand crypto investment opportunities in Germany, as one of our key markets, where we are the first and only firm providing such a comprehensive product suite. This development underscores our commitment to helping investors safely access crypto assets, now and in the future.” The six Xetra-listed crypto ETPs emphasize 21Shares’ leadership in crypto

Regarding public information about Klaipeda Prosecutor Office civil claim concerning AB “Klaipedos nafta” shares granted to employees22.9.2021 18:03:11 CEST | Press release

Public sources of information provided that the Klaipeda Prosecutor Office has submitted a civil claim against AB "Klaipedos nafta" (KN) on a ground of protection of public interest. As suggested by the media, a civil claim is concerning shares granted to employees in 2019. KN granted the shares to employees in 2019 according to the Rules for granting shares, which were approved in the general shareholders meeting. Relevant link: https://view.news.eu.nasdaq.com/view?id=b4561c449403dd0740cf7ee2c12302f9d&lang=en KN has not received a civil claim, thus is unable to provide any comments on the issue. Chief Financial Officer Mindaugas Kvekšas, +370 614 82665

Touax: H1 2021 results22.9.2021 17:45:00 CEST | Press release

PRESS RELEASE Paris, 22 September 2021 – 5.45 p.m. YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION H1 2021 results Restated revenue from activities of €52.5 million, up €1.2 millionResilient business performance with EBITDA of €21.3 million and the Group share of net income amounting to €2.0 millionFavourable outlook with strong investments Touax Group continued to deliver a positive performance while the health crisis caused further disruption. Its results were stable against the same period in 2020, with the exception of sales fees, which declined but were partially offset by sales of owned equipment. The growth in the shipping container leasing business, driven by the shortage of containers, limited asset returns and therefore sales of used containers and sales fees. ANALYSIS OF H1 2021 REVENUE FROM ACTIVITIES The restated presentation of revenue from activities is as follows: Restated Revenue from activities (in € thousand)Q1 2021Q2 2021H1 2021Q1 2020Q2 2020H1 2020

Bolder Surgical announces global launch of the CoolSeal™ Vessel Sealing Platform22.9.2021 16:44:21 CEST | Press release

CoolSeal receives CE mark, Japan PMDA approval; now available in over 20 countries worldwide LOUISVILLE, COLORADO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bolder Surgical today announced the global launch of its CoolSeal™ Vessel Sealing platform. CoolSeal has been in use since October 2020 in the U.S., and with the new international regulatory approvals the devices are available in over 20 countries around the world. Bolder Surgical provides surgeons precision electrosurgical instruments to perform minimally invasive surgery safely and effectively in pediatric and adult procedures including general, gynecological and bariatric surgical applications. The CoolSeal Vessel Sealing suite includes the 3 mm Mini (formerly JustRight Sealer) and the 5 mm Trinity Sealer/Divider/Dissector. Both devices are powered with the gold-standard efficacy of advanced bipolar RF vessel sealing technology. “Having successfully used the 3 mm vessel sealer for many cases in pediatric surgery, the Trinity 5 mm devic